NASDAQ:RPHM Reneo Pharmaceuticals (RPHM) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free RPHM Stock Alerts $1.58 -0.24 (-12.98%) (As of 01:57 PM ET) Add Compare Share Share Today's Range$1.55▼$1.7350-Day Range$1.60▼$1.8652-Week Range$0.98▼$9.45Volume6.14 million shsAverage Volume317,506 shsMarket Capitalization$52.64 millionP/E RatioN/ADividend YieldN/APrice Target$18.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Reneo Pharmaceuticals alerts: Email Address Reneo Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingReduce1.88 Rating ScoreUpside/Downside1,051.6% Upside$18.14 Price TargetShort InterestBearish13.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 19 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.83) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.28 out of 5 starsMedical Sector765th out of 925 stocksPharmaceutical Preparations Industry359th out of 430 stocks 2.9 Analyst's Opinion Consensus RatingReneo Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.88, and is based on no buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageReneo Pharmaceuticals has received no research coverage in the past 90 days.Read more about Reneo Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.80% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 18.7, which indicates bearish sentiment.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently increased by 4.42%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReneo Pharmaceuticals does not currently pay a dividend.Dividend GrowthReneo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPHM. Previous Next 1.8 News and Social Media Coverage News SentimentReneo Pharmaceuticals has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Reneo Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RPHM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reneo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.98% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reneo Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($0.83) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reneo Pharmaceuticals is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reneo Pharmaceuticals is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReneo Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Reneo Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Tomorrow InvestorThe Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest About Reneo Pharmaceuticals Stock (NASDAQ:RPHM)Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Read More RPHM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPHM Stock News HeadlinesMay 13, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHMMay 13, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKureMay 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 13, 2024 | businesswire.comRPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to ShareholdersMay 13, 2024 | markets.businessinsider.comReneo Pharmaceuticals, OnKure To MergeMay 13, 2024 | marketwatch.comReneo Pharmaceuticals Sets Reverse Merger With OnKureMay 13, 2024 | msn.comReneo Pharmaceuticals gains on deal to merge with OnKureMay 13, 2024 | globenewswire.comReneo Pharmaceuticals and OnKure Announce Proposed MergerMay 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 11, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Decreased by AnalystMay 10, 2024 | markets.businessinsider.comMaintaining Hold on Reneo Pharmaceuticals Amidst Strategic Uncertainties and Pipeline SetbacksMay 7, 2024 | finanznachrichten.deReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | investorplace.comRPHM Stock Earnings: Reneo Pharmaceuticals Beats EPS for Q1 2024May 7, 2024 | finance.yahoo.comReneo Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 7, 2024 | globenewswire.comReneo Pharmaceuticals Reports First Quarter 2024 Financial ResultsApril 14, 2024 | thestreet.comReneo Pharmaceuticals Inc.March 31, 2024 | markets.businessinsider.comSell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price TargetMarch 28, 2024 | benzinga.comReneo Pharmaceuticals: Q4 Earnings InsightsMarch 28, 2024 | investorplace.comRPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023March 28, 2024 | finanznachrichten.deReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business UpdateMarch 28, 2024 | globenewswire.comReneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business UpdateFebruary 14, 2024 | uk.finance.yahoo.comReneo Pharmaceuticals, Inc. (RPHM)February 14, 2024 | uk.finance.yahoo.comReneo Pharmaceuticals, Inc. (RPHM)January 30, 2024 | investing.comReneo Pharmaceuticals Inc (RPHM)December 27, 2023 | msn.comWhy Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionDecember 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC)December 16, 2023 | markets.businessinsider.comHold Rating on Reneo Pharmaceuticals Following Lead Drug Trial Failure and Strategic UncertaintySee More Headlines Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/13/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RPHM CUSIPN/A CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$18.14 High Stock Price Target$35.55 Low Stock Price Target$3.00 Potential Upside/Downside+995.3%Consensus RatingReduce Rating Score (0-4)1.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,390,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.76% Return on Assets-60.10% Debt Debt-to-Equity RatioN/A Current Ratio29.83 Quick Ratio29.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.66 per share Price / Book0.62Miscellaneous Outstanding Shares33,420,000Free Float27,439,000Market Cap$55.34 million OptionableOptionable Beta0.22 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Michael G. Grey (Age 71)Founder & Executive Chairman Comp: $100kMr. Gregory J. Flesher (Age 54)President, CEO & Director Comp: $800.45kMr. Michael P. Cruse (Age 52)Chief Operating Officer Comp: $535.47kMs. Ashley F. Hall J.D. (Age 52)Chief Development Officer Comp: $661.55kMs. Jennifer P. LamSVP of Finance & Administration and Principal Financial & Accounting OfficerDr. Alejandro Dorenbaum M.D. (Age 63)Chief Medical Officer Comp: $477.65kMs. Lynn Purkins Ph.D.Senior Vice President of Global DevelopmentMore ExecutivesKey CompetitorsCelularityNASDAQ:CELUAnnovis BioNYSE:ANVSImmix BiopharmaNASDAQ:IMMXCalciMedicaNASDAQ:CALCAEON BiopharmaNASDAQ:AEONView All CompetitorsInsiders & InstitutionsMarquette Asset Management LLCBought 73,770 shares on 5/7/2024Ownership: 0.221%Fifth Lane Capital LPSold 7,365 shares on 5/2/2024Ownership: 0.098%BML Capital Management LLCBought 863,684 shares on 4/23/2024Ownership: 6.517%Octagon Capital Advisors LPSold 29,870 shares on 2/15/2024Ownership: 6.754%Pale Fire Capital SEBought 15,249 shares on 2/14/2024Ownership: 0.090%View All Insider TransactionsView All Institutional Transactions RPHM Stock Analysis - Frequently Asked Questions Should I buy or sell Reneo Pharmaceuticals stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" RPHM shares. View RPHM analyst ratings or view top-rated stocks. What is Reneo Pharmaceuticals' stock price target for 2024? 8 analysts have issued twelve-month price objectives for Reneo Pharmaceuticals' stock. Their RPHM share price targets range from $3.00 to $35.55. On average, they anticipate the company's share price to reach $18.14 in the next year. This suggests a possible upside of 1,051.6% from the stock's current price. View analysts price targets for RPHM or view top-rated stocks among Wall Street analysts. How have RPHM shares performed in 2024? Reneo Pharmaceuticals' stock was trading at $1.60 on January 1st, 2024. Since then, RPHM shares have decreased by 1.6% and is now trading at $1.5750. View the best growth stocks for 2024 here. When is Reneo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our RPHM earnings forecast. How were Reneo Pharmaceuticals' earnings last quarter? Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) announced its earnings results on Thursday, March, 28th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.15. When did Reneo Pharmaceuticals IPO? Reneo Pharmaceuticals (RPHM) raised $101 million in an initial public offering on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. Who are Reneo Pharmaceuticals' major shareholders? Reneo Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BML Capital Management LLC (6.52%), Marquette Asset Management LLC (0.22%) and Fifth Lane Capital LP (0.10%). Insiders that own company stock include Ashley Hall, Bali Muralidhar, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell and Vineet R Jindal. View institutional ownership trends. How do I buy shares of Reneo Pharmaceuticals? Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RPHM) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldUrgent Nvidia WarningAltimetryConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
